These data are consistent with previous studies for the NOS-TFs signature showing that it did not correlate with poor outcome in breast cancer [46], and with previous observations that mammaprint and proliferation signatures have only been shown to be prognostic in ER+ and HER2- breast cancer subtypes [10]. This evidence concerns the gene ESR1 and breast cancer.